BioSpace News Archive

The autoimmune disorder of immune thrombocytopenia outcomes in an unusually low level of platelets.

The global canine arthritis treatment market is expected to weave a strong web of growth during the forecast period of 2019 to 2029.

Strengthens Kronos’ clinical development pipeline and long-term commitment to leverage transcriptional regulatory networks to unlock historically undruggable targets in oncology Includes two clinical stage SYK inhibitors (entospletinib and lanraplenib) with initial development planned in biomarker defined subset of acute myelogenous leukemia

-- Offer price increased from €39.00 to €43.00 per QIAGEN share in cash -- Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares -- QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares

3M is sharing results of the global efforts the company launched in March to combat fraud connected to the COVID-19 pandemic.

BioSpace Inc., the leader in life sciences news and careers, announced today that they have released the BioSpace 2020 Salary Report.

Imprivata®, the digital identity company for healthcare, today announced its selection as the #1-ranked company for Client Satisfaction for Identity Governance solutions in the 2020 Black Book™ Survey of the top healthcare industry technology security solutions.

Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics Potential for Human Monoclonal Antibody COVID-19 Therapeutics to be Developed as a Result of the Collaboration NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collab

SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 12:01 a.m. ET on July 17, 2020. SCYNEXIS common stock will begin trading on a split-adjusted basis commencing upon market open on July 17, 202

Ambra Health, makers of the leading cloud-based, medical image management suite and Invenio Imaging, a leader in rapid intraoperative tissue imaging with Stimulated Raman Histology (SRH), today announced a partnership that integrates Ambra’s image management technology with Invenio’s NIO Laser Imaging System.